Gene therapy and stem cells save limb
09 December, 2009 by Staff WritersTreatment could help improve blood flow and decrease tissue death in individuals with diabetes.
Xenotransplantation patient less reliant on insulin
07 December, 2009 by Tim DeanFirst patient to receive Living Cell Technology's Diabcell implant has reduced insulin dose.
New test finds chink in cancer's armour
24 November, 2009 by Tim DeanAustralian scientists develop rapid and easy assay that could lead to a new cancer tests and targeted chemotherapy drugs.
New kidney cancer drug gets TGA tick
19 November, 2009 by Tim DeanNovartis Australia has received Therapeutic Goods Administration approval for Afinitor.
Biotech Market Spotlight: QRxPharma and Living Cell Technology
16 November, 2009 by Tim DeanQRxPharma raises $21.6 m and Living Cell Technology offers share purchase plan.
Priority status granted to ChemGenex's leukaemia treatment
10 November, 2009 by Tim DeanFDA grants ChemGenex Priority Review for New Drug Application for Omapro.
Feature: ‘Gatekeeper’ protein protects injured brain
06 November, 2009 by Graeme O'NeillAfter a stroke or physical trauma, toxic metal ions flood into brain cells. Seong-Seng Tan has found a way to close the floodgates until the hazard passes.
Opinion: Biotechnology and the future of health
26 October, 2009 by Staff WritersBiotechnology promises untold benefits to humanity, but our mindsets are still stuck in the 20th century. Anna Lavelle stresses the need for change.
Feature: Multiplexing cancers of unknown primaries
13 October, 2009 by Kate McDonaldA new test under development could aid in the currently problematic diagnosis of cancers of unknown primary.
Feature: Big questions about obesity
25 September, 2009 by Graeme O'NeillObesity is more than just a psychological problem. Researchers like Mark Febbraio are serious about understanding more about the biology underlying obesity.
Evolution sheds light on breast cancer
24 September, 2009 by Staff WritersMissense mutations in the ATM gene associated with breast cancer risk.
Feature: Targeting leukaemia
21 September, 2009 by Tim DeanAustralian-US pharmaceutical company, ChemGenex, is close to bringing a new targeted drug to market, with implications for chronic myelogenous leukaemia and other blood-borne cancers.
NCRIS rolls out upgraded biotech labs
18 September, 2009 by Staff WritersUNSW and Macquarie open upgraded labs for CV, cancer and biofuels research.
Feature: Genetic headache
10 September, 2009 by Tim DeanWhat does the mutiny on the Bounty have to do with the genetics of migraine? Lyn Griffiths talks about her voyage to Norfolk Island, the last home of the Bounty mutineers, to find out what they can teach us about migraine.
ChemGenex targets NDA for OMAPRO
09 September, 2009 by Tim DeanNew drug application for targeted anti-leukaemia drug completed, mid-2010 launch expected.
